Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Sangamo Therapeutics, Inc. - Common Stock
(NQ:
SGMO
)
0.3771
-0.0129 (-3.31%)
Streaming Delayed Price
Updated: 10:55 AM EST, Feb 11, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sangamo Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Sangamo Therapeutics Announces First Quarter 2025 Earnings Call
May 06, 2025
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease
May 06, 2025
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
April 28, 2025
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Expert Outlook: Sangamo Therapeutics Through The Eyes Of 11 Analysts
↗
January 27, 2025
Via
Benzinga
9 Analysts Have This To Say About Sangamo Therapeutics
↗
December 31, 2024
Via
Benzinga
Friday's pre-market session: top gainers and losers
↗
April 04, 2025
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Via
Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
April 04, 2025
Via
Benzinga
US Stocks Likely To Open Lower After The Worst Selloff Since 2020: Tariff Announcement Was '100% Smoot Hawley Disguised As Thoughtful Policy,' Says Expert
↗
April 04, 2025
U.S. stock futures continued to decline on Friday after a bloodbath on Thursday following the introduction of Donald Trump's tariffs.
Via
Benzinga
Topics
Government
Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
↗
April 04, 2025
Via
Benzinga
Guess, Simulations Plus And 3 Stocks To Watch Heading Into Friday
↗
April 04, 2025
Via
Benzinga
RH, Five Below, Sangamo, Bank Of America, Tesla: Why These 5 Stocks Are On Investors' Radars Amid Trump Tariff Meltdown
↗
April 03, 2025
The stock market experienced a significant downturn today, with the S&P 500 dropping nearly 5% to 5,396.52, marking its worst session since September 2022.
Via
Benzinga
Topics
Government
Stocks
Eli Lilly Stock Drops As Trump Tariff Chaos Hits Markets, But Retail Finds Comfort In Big Pharma’s Exemption
↗
April 03, 2025
On Stocktwits, message volume about Lilly jumped by 23% over the past 24 hours, with retail sentiment turning more ‘bullish.’
Via
Stocktwits
Topics
Government
Stocks
World Trade
What's going on in today's after hours session
↗
April 03, 2025
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.
Via
Chartmill
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
April 03, 2025
Via
Benzinga
Sangamo Therapeutics Stock Surges After The Bell: What's Going On?
↗
April 03, 2025
Sangamo Therapeutics shares are surging in Thursday's after-hours session after the company announced a new agreement with pharmaceutical giant Eli Lilly And Co.
Via
Benzinga
Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System
April 03, 2025
From
Sangamo Therapeutics, Inc.
Via
Business Wire
8 Analysts Assess Sangamo Therapeutics: What You Need To Know
↗
March 18, 2025
Via
Benzinga
US Futures Show Caution Among Investors Ahead Of FOMC Meeting: Analysts Say Only Certainty Is That 'Things Will Remain Uncertain For The Time Being'
↗
March 18, 2025
U.S. stock futures were flat on Tuesday after a bounce back on Monday. Futures of all four benchmark indices were mixed in premarket trading.
Via
Benzinga
IHS Holding, HealthEquity And 3 Stocks To Watch Heading Into Tuesday
↗
March 18, 2025
Via
Benzinga
Sangamo Therapeutics Retail Traders Keep The Faith Even As Stock Slides After-Hours On Q4 Miss
↗
March 18, 2025
Several optimistic users expressed confidence in the company securing a third potential agreement with a major pharma for its adeno-associated virus (AAV) capsid, STAC-BBB.
Via
Stocktwits
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
March 17, 2025
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Earnings Scheduled For March 17, 2025
↗
March 17, 2025
Via
Benzinga
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference
March 06, 2025
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Pfizer Discontinues Hemophilia Gene Therapy Beqvez As Interest Wanes
↗
February 21, 2025
Pfizer has discontinued Beqvez for hemophilia B due to low patient demand and will focus on alternative treatments, including its approved therapy, Hympavzi.
Via
Benzinga
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile
February 06, 2025
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
January 02, 2025
From
Glancy Prongay & Murray LLP
Via
Business Wire
Sangamo Therapeutics, Inc. (SGMO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
January 02, 2025
From
Law Offices of Howard G. Smith
Via
Business Wire
Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
January 02, 2025
From
The Law Offices of Frank R. Cruz
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
December 31, 2024
Via
Benzinga
Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide
↗
December 31, 2024
Via
Benzinga
Topics
Stocks
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today